Immune compromise and prevalence of Candida vulvovaginitis in human immunodeficiency virus-infected women

Obstetrics and Gynecology

Volumn 90, Issue 2, 1997, Pages 252-256

  Duerr, Ann ^a   Sierra, Marcelino F ^b   Feldman, Joseph ^b   Clarke, Lorraine M ^b   Ehrlich, Ira ^b   Dehovitz, Jack ^b  

^a NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN;

ADULT; AGED; ARTICLE; CANDIDA ALBICANS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNOCOMPETENCE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; PREVALENCE; PRIORITY JOURNAL; TORULOPSIS GLABRATA; VAGINA CANDIDIASIS; VAGINA FLORA; YEAST;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; CANDIDIASIS, VULVOVAGINAL; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV SERONEGATIVITY; HIV SEROPOSITIVITY; HUMANS; IMMUNOCOMPROMISED HOST; PREVALENCE; PROSPECTIVE STUDIES;

EID: 0030809252     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0029-7844(97)00253-6     Document Type: Article

References (17)

1. Korting HC, Ollert M, Georgii A, Fröschl M. In vitro susceptibilities and biotypes of Candida albicans isolates from the oral cavities of patients infected with human immunodeficiency virus. J Clin Microbiol 1988;26:2626-31.
2. Whelan WL, Kirsch DR, Kwon-Chung KJ, Wahl SM, Smith PD. Candida albicans in patients with the acquired immunodeficiency syndrome: Absence of a novel or hypervirulent strain. J Infect Dis 1990;162:513-8.
3. Franker CK, Lucartorto FM, Johnson BS, Jacobson JJ. Characterization of the mycoflora from oral mucosal surfaces of some HIV-infected patients. Oral Surg Oral Med Oral Pathol 1990;69:683-7.
4. Brawner D, Cutler J. Oral Candida albicans isolates from nonhospitalized normal carriers, immunocompetent hospitalized patients, and immunocompromised patients with or without acquired immunodeficiency syndrome. J Clin Microbiol 1989;27:1335-41.
5. Just G, Steinheimer M, Böttinger C, Helm EB, Stille W. Change of causative organisms under antifungal treatment in immunosuppressed patients with HIV infections. Mycoses 1989;32:47-51.
6. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992; 41(no. RR-17):1-19.
7. Rhoads JL, Wright DC, Redfield RR, Burke DS. Chronic vaginal candidiasis in women with human immunodeficiency virus infection. JAMA 1987;257:3105-7.
8. Imam N, Carpenter CC, Mayer KH, Fisher A, Stein M, Danforth SB. Hierarchical pattern of mucosal Candida infections in HIV-seropositive women. Am J Med 1990;89:142-6.
9. Spinillo A, Michelone G, Cavanna C, Colonna L, Capuzzo E, Nicola S. Clinical and microbiological characteristics of symptomatic vulvovaginal candidiasis in HIV-seropositive women. Genitourin Med 1994;70:268-72.
10. White M. Is vulvovaginal candidiasis an AIDS-related illness? Clin Infect Dis 1996;22(suppl. 2):S124-7.
11. Clarke LM, Duerr A, Feldman J, Sierra MF, Daidone BJ, Landesmann SH. Factors associated with cytomegalovirus infection among human immunodeficiency virus type 1-seronegative and -seropositive women from an urban community. J Infect Dis 1996;173:77-83.
12. Hosmer O, Lemenshow S. Applied logistical regression. New York: Wiley, 1989:135-73.
13. Bodey GP. Candidiasis: Pathogenesis, diagnosis, and treatment. New York: Raven Press, 1993.
14. Fidel P, Sobel J. The role of cell-mediated immunity in candidiasis. Trends Microbiol 1994;2:202-6.
15. Witkin S. Immunologic factors influencing susceptibility to recurrent candidal vaginitis. Clin Obstet Gynecol 1991;34:662-8.
16. Sobel J. Candidal vulvovaginitis. Clin Obstet Gynecol 1993;36:153-65.
17. Clerici M, Shearer GM. A TH1→TH2 switch is a critical step in the etiology of HIV infection. Immunol Today 1993;14:107-11.